ABSTRACT Background The NLRP3 inflammasome‐mediated inflammatory response plays a critical role in endothelial dysfunction. Danqi pill (DQP), a Chinese patent medicine composed of Salvia miltiorrhiza and Panax notoginseng , has demonstrated protective effects on endothelial cells, though its underlying mechanisms remain incompletely understood. Methods Human umbilical vein endothelial cells (HUVECs) were subjected to oxygen‐glucose deprivation (OGD) to simulate ischemic injury. Cell viability, migration, reactive oxygen species (ROS) production, mitochondrial membrane potential, and protein expression related to the NLRP3 inflammasome and Src homology 2‐containing protein tyrosine phosphatase 2 (SHP2) were assessed. Results DQP (600 μg/mL) protected HUVECs against OGD‐induced injury by enhancing cell viability and migration, reducing ROS production and cell death, and preserving mitochondrial membrane potential. Mechanistically, DQP promoted the translocation of SHP2 to mitochondria, which subsequently suppressed ROS generation and NLRP3 inflammasome activation. Conclusion These findings reveal that DQP attenuates OGD‐induced injury in HUVECs via SHP2‐ROS‐NLRP3 axis.
Zhong et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: